Stock Ratings / Health Care / ICLR / earnings

CRL (63) MEDP (80) INCY (84) IQV (64) ⌘ Pro Terminal →

ICON plc (ICLR) Next Earnings Date & Expected ±9.7% Move

$211.36 -1.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $211.14

ICON plc (ICLR) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (steady margins, 3% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate) →

ROARABLE B- • BUY Cap $16.50B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICLR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ICLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, ICON plc (NASDAQ: ICLR) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $211.36 (-1.91% 1D, market cap $16.50B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, ICLR ranks #77 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ICLR compare to CRL and MEDP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ICLR carries a Roarable B- (71/100 RQD), trailing P/E of 71.9x, gross margin of —, and ROIC of 3.1%. By comparison, CRL (Charles River Laboratories International Inc.) holds a C grade (63/100 RQD, P/E N/A, ROIC 0.4%, cap $17.95B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICLR?

▼

Per ICLR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001060955), ICON plc generated $8.25B in revenue (+0.8% YoY), $229.3M in net income, and $862.0M in free cash flow against $16.27B in total assets and $2.87B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 72x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $211.15 (-0.10%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 10.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICLR)Realized 20D OHLCV Swing Band: ±9.7%

Deterministic 5-Pillar Attribution (71/100 Composite)

🔍 WHY ICLR SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (25% of score)

20D Institutional Volume Accumulation (±9.7% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (23% of score)

FRED Regime × Technicals: 95% of 52W Range • RSI-14 at 75.7 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$164.34+6% Next Q

Q2 (-2Q)

Grade B-$174.19+5% Next Q

Q3 (-1Q)

Grade B-$182.98+15.5% Next Q

Current

Grade B-$211.36+6.8% Hist 90D α

Trajectory: C+ (63) → B- (71)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ICLR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, ICLR faces multiple-compression risk if 71.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 72x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($173.67) or 200D SMA ($146.13) invalidates the momentum regime and cuts Target Base ($223.72) toward Bear Floor ($173.32).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICLR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICLR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 71%NO 29%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±9.7% Swing Band

±$20.50 Expected Swing

MODEL EARNINGS SETUP GAUGE

ICLR Quantitative Pre-Earnings Setup: 71/100

Trailing EPS: $3.00 • YoY Revenue Growth: 0.8%

Model Bullish Setup (71/100)Model Risk Weight (29/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$8.25B	$229.3M	$862.0M	52%
FY 2024	2024-12-31	$8.19B	$739.1M	$1.12B	28.6%
FY 2023	2023-12-31	$8.05B	$554.2M	$798.6M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ICLR & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on ICLR
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICLR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +88.76%▲ ASCENDING CHANNEL

2026-11-02O $214.2H $215.5L $211.4C $211.4VOL 1.80M

RES: $221.4SUP: $160.1SMA50: $173.7SMA200: $146.1

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICLR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICLR Butterfly Map → + Track ICLR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

46.6%/yr Implied 5Y Growth

vs. +0.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICLR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICLR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICLR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICLR)

Health Care Rank #77 of 1016 ⚔️ CRL vs ICLR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICLR vs. CRL, MEDP, INCY, IQV)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ICON plc (ICLR) ranks #77 by composite RQD confidence (71/100, grade B-) and #77 by equity capitalization ($16.50B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 84/100 (A-) compared with ICLR at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICLR ACTIVE ICON plc	B-	71/100	71.9x	—	3.1%	-1.91%	$16.50B	Benchmark Subject
CRL Charles River Laboratories International Inc.	C	63/100	—	—	0.4%	-4.44%	$17.95B	/crl-vs-iclr →
MEDP Medpace Holdings Inc.	B+	80/100	42.0x	—	27.9%	-3.77%	$18.95B	/medp-vs-iclr →
INCY Incyte Corp.	A-	84/100	18.4x	92.8%	42.4%	+3.07%	$23.68B	/incy-vs-iclr →
IQV IQVIA Holdings Inc.	C	64/100	33.3x	—	9.4%	-2.81%	$45.33B	/iqv-vs-iclr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001060955

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ICON plc (ICLR) reported GAAP revenue of $8.25B (+0.8% vs. FY2024 revenue of $8.19B , and +2.4% cumulative change since FY2023) , GAAP net income of $229.3M, operating cash flow of $1.04B, and free cash flow of $862.0M (-22.9% YoY). On the balance sheet, ICLR closed FY2025 with $16.27B in total assets against $2.87B in total debt (Altman Z-Score: 2.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$8.25B	$229.3M	$1.04B	$862.0M	$16.27B	$2.87B
FY2024 (FY)	2024-12-31	$8.19B	$739.1M	$1.29B	$1.12B	$16.63B	$3.40B
FY2023 (FY)	2023-12-31	$8.05B	$554.2M	$1.16B	$798.6M	$9.67B	$2.26B

3. ICLR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICLR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ICLR compare to CRL and MEDP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ICLR?

Where is ICLR trading relative to its 50-day, 200-day, and 52-week technical levels?

ICLR last traded at $211.36 (-1.91% on volume of 2,580,652 shares), positioning the stock +21.70% above its 50-day simple moving average ($173.67) and +44.64% above its 200-day simple moving average ($146.13). Across its 52-week range of $66.57 to $219.04, ICLR sits at the 95.0% percentile with a 14-day RSI of 75.7 (OVERBOUGHT (>70)) and an implied next-earnings move of ±9.7% ($190.86 to $231.86).

ICLR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ICLR's next earnings date?

Based on SEC filing cadence, ICON plc (ICLR)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ICLR stock expected to move on earnings?

Volatility modeling currently projects a ±9.7% event move for ICLR, spanning a range between $190.86 and $231.86.

Direct Sub-Reports: ICLR RQD Cockpit ICLR 12M Forecast ICLR Earnings & Move ICLR Dividends & DRIP ICLR Insiders & 13F ICLR Whale Options ICLR Profit Sankey ICLR News & Why

Sector Peer Dials

Compare →

CRL C

Charles River Laboratories International Inc.

63 /100

MEDP B+

Medpace Holdings Inc.

ICLR Core Snapshot

Market Cap $16.50B

Trailing / Fwd P/E 71.9x / 66.9x

Gross Profit Margin —

Return on Capital (ROIC) 3.1%

Free Cash Flow Yield 5.22%

12M Base Price Target $223.72

FREE TRADER TOOLS

Own ICLR Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With ICLR → 🏆 Trade ICLR in $100K Prop Arena →

ICLR Wire

Why It Moved →

Direct Company Event Yahoo Finance • 8h ago

ICON (ICLR) Could Be 15% Overvalued After Record Wins And Fresh Buyback

Direct Company Event StockInvest.us • 11h ago

Icon Stock Price Forecast. Should You Buy ICLR?

Direct Company Event Moomoo • 14h ago

ICON ($ICLR) Releases Q3 2026 Earnings, Stock Rises

Direct Company Event Yahoo Finance • 17h ago

ICON (ICLR) Stock Could Be A Bargain After Cash Flow Rebound

Direct Company Event TradingView • 20h ago

ICON plc Estimates – NASDAQ:ICLR

ROARABLE RATING BRIEF • RQD 71/100 (B-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ICLR — ICON plc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:14:18Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ICON plc scores 71 out of 100, a B- grade labeled "Roarable Buy — Sound Institutional Accumulation." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 3.1%; FCF yield 5.22%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 11/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 16/20 (Beta 1.08; sector sensitivity), and Forensic Balance Sheet at 14/20 (Altman Z 2.2; Piotroski F 7/9; Debt/Equity 0.31). For a prospective investor, the strongest pillar is institutional positioning, which is the main upside driver the rating identifies. The weakest pillar is the cash engine, where a 3.1% ROIC sits against a 71.9 trailing P/E, indicating that the valuation depends heavily on future earnings expansion rather than current returns on capital. Insider conviction is moderate, and the balance sheet is rated sound but not exceptional. Taken together, the rating frames the stock as one where institutional support is strong while valuation tradeoffs remain significant.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
215.48	$16.5B	71.9	66.9	31.7	3	0%	1.08	$66.57 - $219.04	3.1%

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$8251.3M	$442.8M	$229.3M	N/A	$862.0M	$647.3M	$2872.6M
FY 2024	$8189.0M	$1032.4M	$739.1M	N/A	$1118.6M	$538.8M	$3396.4M
FY 2023	$8054.9M	$904.7M	$554.2M	N/A	$798.6M	N/A	$2261.8M

Per the SEC financials, revenue rose modestly across the three periods while net income fell from $739.1M in FY 2024 to $229.3M in FY 2025. Market data shows an operating margin of 5.4% and a net margin of 2.8%, with ROIC at 3.1%. The Altman Z-Score of 2.2 and Piotroski F-Score of 7/9 are cited in the forensic pillar of the RQD rating, and Debt/Equity is listed at 0.31. Free cash flow was $862.0M in FY 2025 against $1118.6M in FY 2024.

Open Questions

What drove the drop in net income from $739.1M (FY 2024) to $229.3M (FY 2025), and is it recurring?
What are the scale and timing of the record wins and fresh buyback referenced in the news?
What specific earnings figures were reported in Q3 2026?
Which institutions and insiders are accumulating, and at what size?
What are the company's specific products, customers, and revenue mix?

ICLR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ICON plc (ICLR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ICLR Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 8h ago

ICON (ICLR) Could Be 15% Overvalued After Record Wins And Fresh Buyback

Yahoo Finance report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 11h ago

Icon Stock Price Forecast. Should You Buy ICLR?

StockInvest.us report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 14h ago

ICON ($ICLR) Releases Q3 2026 Earnings, Stock Rises

Moomoo report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 17h ago

ICON (ICLR) Stock Could Be A Bargain After Cash Flow Rebound

Yahoo Finance report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 20h ago

ICON plc Estimates – NASDAQ:ICLR

TradingView report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 23h ago

Icon PLC (ICLR) Shares Surge 3.6% -- What GF Score of 94 Tells I

GuruFocus report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST The Globe and Mail • 1d ago

Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Beam Therapeutics (BEAM)

The Globe and Mail report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Results arrive after market close October 27 for ICON (ICLR), with an earnings call October 28.

Stock Titan report covering ICON plc (ICLR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ICLR Bull vs. Bear Conversation Board — What's Your Call at $211.36?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ICLR 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $254.27 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ICLR (B- • RQD 71/100) a Buy at $215.48?

Welcome to the ICLR (ICON plc) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (71.9x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $174.54 (-19.0%)

Spot @ $215.48

Pump the brakes on ICLR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ICLR, but look at what you are paying: 71.9x trailing P/E with tightening sector spreads. Unless ICON plc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $273.66 (+27.0%)

Spot @ $215.48

ICLR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ICLR, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $215.48 (52-wk range $66.57 - $219.04), any beat on forward guidance forces shorts and underweight funds to chase.